Initially described in 1982, the persistent polyclonal B-cell lymphocytosis (PPBL) is characterized by a chronic, stable, persistent and polyclonal lymphocytosis, the presence of binucleated lymphocytes in the peripheral blood and a polyclonal increase in serum immunoglobulin-M (IgM). 1 In this apparently benign entity, we showed that PPBL was associated with recurrent chromosomal abnormalities and a typical cytogenetic profile including isochromosome 3q, þ i(3q), premature chromosome condensation (PCC), both abnormalities in the same patient or chromosomal instability. 2 Despite clinical and polyclonal lymphocytosis stability, the long-term follow-up is not yet well established.
We analyze and report here the long-term follow-up of 111 patients with typical PPBL. PPBL was diagnosed in 91 women (82%) (median age 40 years, range 19-66 years) and 20 men (median age 40.9 years, range 28-57 years). The patients, smokers in 98% of cases, were either asymptomatic or had minor and nonspecific complaints, such as fatigue. Physical examination was usually within normal limits, except for a mild splenomegaly present in 10% of cases. PPBL was diagnosed when blood smear analysis revealed the presence of a variable number of binucleated lymphocytes, whatever the lymphocyte count. At the time of diagnosis, 83% of patients presented with mild lymphocytosis and 17% with a lymphocyte count below 4 Â 10 9 / l. The median lymphocyte count was 5.45 Â 10 9 /l, with a range of 2.45-20.52 Â 10 9 /l. In all cases, peripheral blood examination showed typical binucleated lymphocytes, which were present with a variable percentage (median 4%, range 1-40%). Peripheral blood flow cytometry showed a polyclonal B-cell lymphocytosis in all cases, with an expansion of the B CD19-positive and CD5-negative lymphocytes pool. Both kappa and lambda light chain were expressed in all cases, confirming the B-cell polyclonal expansion. The median of polyclonal serum IgM level was 6.0 g/l (normal: 0.5-2.7 g/l), with a range of 1.2-17.3 g/l. Ninety-eight patients underwent conventional cytogenetic analysis (CCA). Isochromosome þ i(3q) was present in 34% (33 of 98 patients), PCC in 8% (8 of 98 patients) and both abnormalities in 31% (30 of 98 patients). CCA showed neither þ i(3q) nor PCC in 28% (27 of 98 patients). Fluorescence in situ hybridization (FISH) was performed in 84 cases. Isochromosome þ i(3q) was studied in interphase with alphasatellite chromosome 3-specific (SO CEP3) and LSI 3 0 BCL6 (3q27) break-apart probes obtained from Abott Molecular (Rungis, France). Isochromosome þ i(3q) was detected in 71% (60 of 84 patients). We also combined CCA and FISH in 84 patients: after FISH, þ i(3q) was detected in 17 patients with negative CCA and was confirmed in 43 patients with positive CCA. CCA and FISH were both negative in 24 cases.
After a median follow-up of 4.4 years (0.5-29 years) (Figure 1 ), PPBL patients presented a stable clinical and biological course in 99 of 111 cases (89%). In two patients, we noticed a decrease of lymphocytosis and the number of binucleated lymphocytes, but isochromosome þ i(3q) persisted 2 years after stopping tobacco use. 2 In our series, six patients died: one heavy smoker patient from pulmonary cancer 9 years after PPBL diagnosis, 1 from myocardial infarction, 1 from cerebral aneurysm rupture, 2 deaths from unknown cause and 1 from diffuse large B-cell lymphoma described below. Two patients had IgM monoclonal gammopathy of undetermined significance (MGUS) at the time of PPBL diagnosis. Two other patients developed IgM MGUS (serum IgM, 6.9 g/l and 12.88 g/l) 12 and 22 years after PPBL diagnosis, respectively. In these four cases, no bone marrow biopsy was performed. IgM gammopathy remained asymptomatic and stable after a median follow-up of 102 months (range 52-348). Two patients presented with pulmonary cancer in the clinical course of PPBL and one patient developed cervical cancer 12 years after the diagnosis of PPBL. A malignant nonHodgkin's lymphoma was also observed in three additional patients: two patients presented with diffuse large B-cell lymphoma (DLBCL) and one patient with a splenic marginal zone lymphoma (SMZL).
Among the three patients, the first case was a 34-year-old woman, smoker, with typical PPBL presenting at diagnosis with a mild absolute lymphocytosis (6.6 Â 10 9 /l) with 3% binucleated lymphoid cells. Peripheral blood flow cytometry analysis showed a polyclonal (kappa/lambda ratio: 2.7) lymphocytosis with predominant B CD19 þ lymphocytes (59%). Supernumerary isochromosome þ i(3q) without PCC was identified both by CCA and FISH; chromosomal instability was also present. Three years after PPBL diagnosis, the patient developed axillary lymphadenopathy. Histological examination showed DLBCL. Peripheral blood flow cytometry displayed a monoclonal B-cell proliferation with 64% CD19 þ , kappa þ , CD5 À and CD10 À lymphoid cells. CCA of the lymph node showed a complex karyotype: 42-44, XX, der(2) t(2;?)(q37;?), del(6)(p23), add(7)(p22), add(12)(p13), À13, À15, À16, À17, add(22
Absence of þ i(3q) was confirmed by FISH. The patient developed DLBCL in leukemic phase 3 years after PPBL diagnosis and despite three cycles of ACBVP regimen (doxorubicin, cyclophosphamide, bleomycin, vindesine and prednisone), then second-line chemotherapy, the patient died from progressive disease, 18 months after DLBCL diagnosis. The second case was a 36-year-old man, smoker, who presented with a moderate splenomegaly and a mild lymphocytosis (8 Â 10 9 /l) with 4% binucleated lymphocytes at diagnosis. Peripheral blood flow cytometry showed a B-cell polyclonal proliferation. Supernumerary isochromosome 3q, þ i(3q) was detected after CCA and FISH studies. Chromosomal instability was present but not PCC. He received chlorambucil during 6 months with decrease of splenomegaly and total disappearance of binucleated lymphocytes. However, the beneficial effects of chemotherapy were of short duration, as splenomegaly and binucleated lymphocytes reappeared 2 months after stopping chlorambucil. Nine years after PPBL diagnosis, the patient presented with multiple superficial lymph nodes, and histological examination showed DLBCL with B-lymphocytes that expressed CD20
þ /À , IgD þ without CD5 and CD10. Unfortunately, neither peripheral blood flow cytometry analysis nor CCA was performed at the time of DLBCL diagnosis. He received four cycles of R-ACBVP (rituximab and ACBVP) followed by methotrexate, etoposide and cytarabine. The patient remains in persistent complete remission 2 years after DLBCL diagnosis and lymphocytosis is still absent.
The third case was a 63-year-old woman, smoker, who was diagnosed with PPBL, with 3.8 Â 10 9 /l lymphocytes and 2% binucleated lymphocytes. Flow cytometry analysis showed a B-cell polyclonal proliferation with 68% CD19-positive lymphoid B cells. The patient had no splenomegaly and no lymph nodes. Supernumerary isochromosome þ i(3q) was detected both on CCA and FISH. Moreover, CCA also identified combined trisomy 3 and þ i(3q). Chromosomal instability and PCC were also observed. There was an increase in serum polyclonal IgM (16.7 g/l). During 3 years, three repeated CCAs detected again þ i(3q) and trisomy 3 on each peripheral blood specimen. During the same period, a large splenomegaly appeared and lymphocyte count increased to 30 Â 10 9 /l. The follow-up of peripheral blood flow cytometry showed a progressive increase of the lambda/kappa ratio from 1-4 with appearance of a monoclonal CD19 þ , CD5 À and CD10 À B-cell proliferation. Blood smear analysis did not reveal any binucleated lymphocytes nor villous lymphocytes. Agarose gel serum protein electrophoresis and immunofixation detected a lambda monoclonal pattern for IgM (18.6 g/l). CCA showed again an isochromosome þ i(3q) but without þ 3. The presence of splenomegaly and the CD5 À CD10 À monoclonal B-cell proliferation led us to regard the diagnosis of SMZL. The patient received four cycles of rituximab, fludarabine and cyclophosphamide and is alive 18 months after chemotherapy with no lymphocytosis (0.6 Â 10 9 /l) and no detectable binucleated lymphocytes. In this case, DNA was available from both the lymphoma and PPBL samples at the time of diagnosis and was evaluated for clonality analysis. As expected, amplification of immunoglobulin heavy-chain (IGH) gene rearrangements showed a clear monoclonal band in the lymphoma sample. The lymphoma B cells expressed functional IgHV3-30, with greater (99.6%) than 98% nucleic acid sequence homology to the germ line IgHV3-30. The IgHJ segment used by that case was IGHJ4 and the IGHD segment was IGHDH2-5. We also detected a minor clone having an identical IGH rearrangement (Figures 2 and 3 ) and sequences at PPBL and SMZL diagnosis. Dilution experiments indicated that this clone represented Letters to the Editor approximately 1% of a monoclonal cell line mixed in polyclonal peripheral blood lymphocytes. Persistent polyclonal B-cell lymphocytosis is a rare disorder. We report the follow-up and event-free survival (Figure 1 ) of a cohort of 111 patients. The stability of lymphocyte count over time and the usually indolent clinical course suggest that PPBL remains in most cases a benign disorder. In our study, 89% of patients remain free of symptoms or complications after a median follow-up of 53 months. In the literature, there are reports of only a few PPBL patients who developed cancers, either solid tumors 3 or hematologic malignancies. 4 We report three additional patients developing non-Hodgkin's lymphomas after PPBL diagnosis, two patients with DLBCL and one with SMZL. In two of the three cases, we were not able to demonstrate a direct relationship between the occurrence of PPBL and lymphoma, particularly þ i(3q) at the time of PPBL and malignant lymphoma's diagnosis. We performed clonality analysis in one of the three patients developing SMZL. As expected, the clonality analysis revealed the presence and the evolution of the same clonal population at the time of PPBL and lymphoma's diagnosis, suggesting possible evolution of a preexistent monoclonal subpopulation in PPBL toward a malignant monoclonal population. A clonal disease was previously demonstrated in PPBL possibly increasing the risk of cancer in few cases. 5, 6 Interestingly, four patients presented at the time of diagnosis or developed IgM MGUS, suggesting the possibility to change from PPBL to IgM MGUS and/or Waldenströ ms macroglobulinaemia. Moreover, we also report two cases of pulmonary cancer in two smokers and one case of cervical cancer. The etiology of PPBL remains unclear: the role of tobacco in the occurrence of these cancers is probably dominant. Intravascular B-cell infiltrates, constantly associated with Bcl-2 immunostaining as seen in some lymphomas, have been reported in PPBL patients. 7 Moreover, multiple Bcl-2/IgH gene rearrangements, mostly polyclonal, but possibly leading to oligoclonal expansion, were observed contributing to the emergence of non-Hodgkin's lymphoma. The genetic predisposition, 8 the persistent viral infection, the chromosomal instability 9 or genetic alterations of ataxia-telangiectasiamutated and Rad3-related gene leading to loss of cell differentiation and cell-cycle abnormalities 10 could explain the possibility of increase of the risk of cancer.
In conclusion, the possibility of PPBL to evolve toward a clonal proliferation, malignant lymphoma or secondary solid cancer led us to consider PPBL not as a benign pathology. We recommend a careful and continued clinical and biological long-term follow-up in all PPBL patients.
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280 300 320 340 360 380 400 Figure 2 Analysis of immunoglobulin heavy chain (IGH) gene rearrangements in PPBL and lymphoma samples. Amplification of IGH gene rearrangements was performed using Biomed-2 PCR protocols 11 with primers specific for the framework region 1. Fluorescent PCR products were then analyzed by GeneScanning. The monoclonal rearrangement of the lymphoma sample (bottom) appears as a unique 341 base-pair pick. A band of similar size can be seen among polyclonal rearrangements in the initial PPBL sample (top).
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T aaa gat aac aaa gag gga tat tgt agt ggt ggt agc tgc tac tct gac tac tgg ggc cag gga acc ctg gtc acc -- We have read with interest the editorial by Dr Bergsagel that accompanies the original article by Arzoumanian et al, which explores the complex relationship between cytogenetic abnormalities and clinical outcome in the treatment of patients with multiple myeloma, utilizing the 'Total Therapy' approach advocated by Barlogie et al. 1, 2 We agree that the pursuit of improved patient outcome utilizing the least toxic therapy while maintaining efficacy is a key goal of new drug development in the field, and this goal has come closer to reality over the last decade, primarily through the development of thalidomide, bortezomib and lenalidomide. We also agree that the heterogeneity encountered in myeloma remains a major barrier in dissecting who benefits best from what, with the use of more sensitive and specific tools, such as immunophenotyping, molecular diagnostics and imaging to assess response a priority for ongoing research.
We would concur that achievement of complete response (CR) was rare until the introduction of high-dose therapy followed by autologous stem cell transplant, and this has generally been associated with prolongation in survival. Similarly, clinical trials of novel agents combined with conventional therapy suggest that patients who achieve a CR with these drugs receive clinical benefit. Thus, it is not apparent how improvements in CR rates with novel agents can therefore be considered 'cosmetic,' when they have led to significant prolongation in overall survival, as confirmed in multiple randomized trials. [3] [4] [5] [6] [7] [8] Further, we do not agree that pursuing 'ever higher complete responses' by combining novel agents with conventional agents and/or transplant is unwarranted, especially as historical analyses of survival before and after the introduction of novel agents in clinical practice are showing a positive impact on patient survival, which is the first time in the last 20 years that such a change has been seen. 9, 10 In the second part of the editorial, the commentary is much less clear. First, contrasts are drawn between the E4A03 and VISTA studies, which lack merit. 3, 4 Specifically, the statement that 'the increase in the CR (in the VISTA trial) was not accompanied by an equally dramatic prolongation of overall survival' is not correct, as overall survival for patients receiving VMP versus MP has been significantly superior for the VMP arm at every protocol-specified follow-up point to date. Importantly, the 2-year probabilities of the experimental arms in both studies (VISTA and E4AO3) are identical; are both markedly superior to their respective comparators, and constitute encouraging advances for the treatment of newly diagnosed disease. In our view, the correct conclusion from these trials is that there are now important new therapeutic platforms to build upon, incorporating both bortezomib and lenalidomide, and this is very good news for our patients.
Unfortunately, the text next implies that research clinicians are driven by alternative motives and are overly influenced by corporate rhetoric rather than by a desire to cure the disease.
